Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - Report of the National Multicenter Trial

Pediatrics

Volumn 97, Issue 1, 1996, Pages 7-13

  Rennels, Margaret B ^a,i   Glass, Roger I ^b   Dennehy, Penelope H ^c   Bernstein, David I ^d   Pichichero, Michael E ^e   Zito, Edward T ^f   Mack, Michael E ^f   Davidson, Bruce L ^f,g   Kapikian, Albert Z ^h  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d James N Gamble Inst of Med Res   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f PFIZER INC   (United States)

^g DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ University Hospital Bern   (United States)

Author keywords

rotaviruses; vaccines

Indexed keywords

IMMUNOGLOBULIN A; NEUTRALIZING ANTIBODY; PLACEBO; ROTAVIRUS VACCINE; SIMIAN ROTAVIRUS VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEVER; GASTROENTERITIS; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS; VACCINATION; VIRUS TYPING; VOMITING;

ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; GASTROENTERITIS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; ROTAVIRUS; ROTAVIRUS VACCINES; SEROTYPING; SEVERITY OF ILLNESS INDEX; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 0030053974     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. de Zoysa I, Feachem RG. Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull World Health Organ, 1985;63:569-583
2. Ho M-S, Glass RI, Pinsky PF, Anderson LJ. Rotavirus as a cause of diarrheal morbidity and mortality in the United States. J Infect Dis. 1988;158:1112-1116
3. Vesikari T, Isolauri E, D'Hondt E, Delem A, Andre FE, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984;1:977-981
4. DeMol P, Zissis G, Butzler J-P, et al. Failure of live, attenuated oral rotavirus vaccine [Letter]. Lancet. 1986;2:108
5. Flores J, Perez-Schael I, Gonzalez M, et al Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. Lancet. 1987;1.882-884
6. Lanata CF, Black RE, del Aguila R, et al Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis. 1989;159:452-459
7. Gothefors L, Wadell G, Juto P, Taniguchi K, Kapikian AZ, Glass RI. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. J Infect Dis. 1989;159.753-757
8. Perez-Schael I, Garcia D, Gonzalez M, et al Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine J Med Virol. 1990;30:219-229
9. Rennels MB, Losonsky GA, Young AE, Levine MM An efficacy trial of the rhesus rotavirus vaccine in Maryland. Am J Dis Child. 1990;144: 601-604
10. Madore HP, Christy C, Pichichero M, et al. Field trial of Rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotypes 3 or 1 specificity in infants. J Infect Dis 1992;162 235-243
11. Clark HF, Borian FE, Bell LB, Modesto K, Gouvea V, Plotkin SA. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 1988; 158.570-587
12. Bernstein DI, Smith VE, Sander DS, Pax KA, Schiff GM, Ward RL. Evaluation of WC3 Rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis. 1990;162:1055-1062
13. Midthun K, Greenberg HB, Hoshino Y, Kapikian AZ, Wyatt RG, Chanock RM. Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol. 1985;53:949-954
14. Midthun K, Hoshino Y, Kapikian AZ, Chanock RM. Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4. J Clin Microbiol. 1986,24: 822-826
15. Perez-Schael I, Blanco M, Vilar M, et al. Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants. J Clin Microbiol. 1990,28: 553-558
16. Bernstein DI, Glass RI, Rogers G, Davidson BL, Sack DA, for the US Rotavirus Vaccine Efficacy Group. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995,273:1191-1196
17. Ing DJ, Glass RI, Woods PA, et al. Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine Am J Dis Child. 1991;145:892-897
18. LeBaron CW, Lew J, Glass RI, Weber JM, Ruiz-Palacios GM, Rotavirus Study Group. Annual rotavirus epidemic patterns in North America. JAMA. 1990;264:983-988
19. Ing D, Glass RI, LeBaron CW, Lew JF. Laboratory-based surveillance for rotavirus, United States, January 1989-May 1991. MMWR. 1992;41(SS-3):47-51
20. Losonsky GA, Rennels MB, Lim YL, Krall G, Kapikian AZ, Levine MM Systemic and mucosal immune responses to rhesus rotavirus vaccine MMU 18006. Pediatr Infect Dis J. 1988;7:388-393
21. Ward RL, Bernstein DI, Shukla R, et al. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis 1989;159:79-88
22. Knowlton DR, Spector DM, Ward RL. Development of an improved method for measuring neutralizating antibody to rotavirus. J Virol Methods. 1991;33:127-134
23. Taniguchi K, Ursawa T, Mortia Y, Greenberg HB, Urasawa S. Direct serotyping of human rotavirus in stools by an enzyme-linked immunosorbent assay using serotype 1-, 2-, 3-, arid 4-specific monoclonal antibodies to VP7. J Infect Dis. 1987;155.1159-1166
24. Ward RL, McNeal MM, Clemens JD, et al. Reactivities of serotyping monoclonal antibodies with culture-adapted human rotaviruses J Clin Microbiol. 1991;29:449-456
25. Treanor JJ, Clark HF, Pichichero ME, et al Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants Pediatr Infect Dis J. 1995;14:301-307
26. Govea V, Ho M-S, Glass RI, et al. Serotypes and electropherotypes of human rotavirus in the USA: 1987-1989. J Infect Dis. 1990;162:362-367
27. Matson DO, Estes MK, Burns JW, Greenberg HB, Taniguchi K, Urasawa S. Serotype variation of human group A rotaviruses in two regions of the USA J Infect Dis. 1990;162:605-614
28. Begue RE, Dennehy PH, Huang J, Martin P. Serotype variation of group A rotaviruses over nine winter epidemics in southeastern New England. J Clin Microbiol. 1992;30:1592-1594
29. Woods PA, Gentsch J, Gouvea V, et al. Distribution of serotypes of human rotavirus in different populations. J Clin Microbiol. 1992;30 781-785
30. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 1983,309:72-76
31. Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea J Infect Dis. 1993,168:282-287
32. Losonsky GA, Rennels MB, Kapikian AZ, et al. Safety, infectivity, transmissibility and immunogenicity of rhesus rotavirus vaccine (MMU 18006) infants Pediatr Infect Dis J. 1986;5:25-29
33. Vesikari T, Kapikian AZ, Delem A, Zissis G. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J Infect Dis. 1986;153.832-839
34. Rennels MB, Losonsky GA, Shindledecker CL, et al. Immunogenicity and reactogenicity of lowered doses of rhesus rotavirus vaccine strain 18006 in young children. Pediatr Infect Dis J. 1987;6:260-264
35. Ward RL, Bernstein DI, for the US Rotavirus Vaccine Efficacy Group. Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. Vaccine 1995;13:1226-1232
36. Offit PA, Hoffenberg EJ, Santos N, Gouvea V. Rotavirus-specific humoral and cellular immune response after primary, symptomatic infection. J Infect Dis. 1993;167.1436-1440
37. Losonsky GA, Reymann M. The immune response in primary asymptomatic and symptomatic rotavirus infection in newborn infants. J Infect Dis 1990;161:330-332
38. Matson DO, O'Ryan ML, Herrera I, Pickering LK, Estes MK. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis. 1993;167:577-583
39. Glass RI, Stoll BJ, Wyatt RG, Hoshino Y, Banu H, Kapikian AZ. Observations questioning a protective role for breast-feeding in severe rotavirus diarrhea Acta Paediatr Scand. 1986;75:713-718
40. Rimer HC, Wasserman SS, Flores J, Pichichero ME, Losonsky GA. Rotavirus-specific breast milk antibody in two populations and possible correlates of interference with rhesus rotavirus vaccine seroconversion. J Infect Dis. 1992;165:826-830
41. Rennels MB, Wasserman SS, Glass RI, Keane VA, for the US Rotavirus Efficacy Group Comparison of immunogenicity and efficacy of rhesus rotavirus reassortant vaccines in breast-fed and non-breast-fed children. Pediatrics. 1995;96:1132-1136
42. Ho M-S, Floyd RL, Glass RI, et al. Simultaneous administration of rhesus rotavirus vaccine and oral poliovirus vaccine, immunogenicity and reactogenicity Pediatr Infect Dis J. 1989,8.692-696
43. Migasena S, Simasathien S, Samakoses R, et al. Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavirus vaccine and oral poliovirus vaccine (OPV) in Thai infants. Vaccine. 1995;13:168-174